Medgenics Inc (NASDAQ:GNMX)’s share price was up 11.1% during mid-day trading on Friday . The stock traded as high as $1.60 and last traded at $1.50. Approximately 633,054 shares changed hands during mid-day trading, an increase of 253% from the average daily volume of 179,477 shares. The stock had previously closed at $1.35.
Separately, Jefferies Group reiterated a “hold” rating and issued a $1.50 price target on shares of Medgenics in a research note on Thursday, September 28th.
Medgenics (NASDAQ:GNMX) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. During the same period last year, the company posted ($0.29) EPS. analysts forecast that Medgenics Inc will post -0.88 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Medgenics (GNMX) Trading Up 11.1%” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3148696/medgenics-gnmx-trading-up-11-1.html.
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn?s disease.
Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with MarketBeat.com's FREE daily email newsletter.